Details

Autor(en) / Beteiligte

• Rose, Angela Mc
• Nicolay, Nathalie
• Sandonis Martín, Virginia
• Mazagatos, Clara
• Petrović, Goranka
• Baruch, Joaquin
• Denayer, Sarah
• Seyler, Lucie
• Domegan, Lisa
• Launay, Odile
• Machado, Ausenda
• Burgui, Cristina
• Vaikutyte, Roberta
• Niessen, F Annabel
• Loghin, Isabela I
• Husa, Petr
• Aouali, Nassera
• Panagiotakopoulos, George
• Tolksdorf, Kristin
• Horváth, Judit Krisztina
• Howard, Jennifer
• Pozo, Francisco
• Gallardo, Virtudes
• Nonković, Diana
• Džiugytė, Aušra
• Bossuyt, Nathalie
• Demuyser, Thomas
• Duffy, Róisín
• Luong Nguyen, Liem Binh
• Kislaya, Irina
• Martínez-Baz, Iván
• Gefenaite, Giedre
• Knol, Mirjam J
• Popescu, Corneliu
• Součková, Lenka
• Simon, Marc
• Michelaki, Stella
• Reiche, Janine
• Ferenczi, Annamária
• Delgado-Sanz, Concepción
• Lovrić Makarić, Zvjezdana
• Cauchi, John Paul
• Barbezange, Cyril
• Van Nedervelde, Els
• O'Donnell, Joan
• Durier, Christine
• Guiomar, Raquel
• Castilla, Jesús
• Jonikaite, Indrė
• Bruijning-Verhagen, Patricia Cjl
• Lazar, Mihaela
• Demlová, Regina
• Wirtz, Gil
• Amerali, Marina
• Dürrwald, Ralf
• Kunstár, Mihály Pál
• Kissling, Esther
• Bacci, Sabrina
• Valenciano, Marta

Titel

Vaccine effectiveness against COVID-19 hospitalisation in adults (≥ 20 years) during Omicron-dominant circulation: I-MOVE-COVID-19 and VEBIS SARI VE networks, Europe, 2021 to 2022

Ist Teil von

• Euro surveillance : bulletin européen sur les maladies transmissibles, 2023-11, Vol.28 (47), p.1

Ort / Verlag

Sweden: Centre Europeen pour la Surveillance Epidemiologique du SIDA (European Centre for the Epidemiological Monitoring of AIDS)

Erscheinungsjahr

2023

Link zum Volltext

Quelle

MEDLINE

Beschreibungen/Notizen

• IntroductionThe I-MOVE-COVID-19 and VEBIS hospital networks have been measuring COVID-19 vaccine effectiveness (VE) in participating European countries since early 2021.AimWe aimed to measure VE against PCR-confirmed SARS-CoV-2 in patients ≥ 20 years hospitalised with severe acute respiratory infection (SARI) from December 2021 to July 2022 (Omicron-dominant period).MethodsIn both networks, 46 hospitals (13 countries) follow a similar test-negative case-control protocol. We defined complete primary series vaccination (PSV) and first booster dose vaccination as last dose of either vaccine received ≥ 14 days before symptom onset (stratifying first booster into received < 150 and ≥ 150 days after last PSV dose). We measured VE overall, by vaccine category/product, age group and time since first mRNA booster dose, adjusting by site as a fixed effect, and by swab date, age, sex, and presence/absence of at least one commonly collected chronic condition.ResultsWe included 2,779 cases and 2,362 controls. The VE of all vaccine products combined against hospitalisation for laboratory-confirmed SARS-CoV-2 was 43% (95% CI: 29-54) for complete PSV (with last dose received ≥ 150 days before onset), while it was 59% (95% CI: 51-66) after addition of one booster dose. The VE was 85% (95% CI: 78-89), 70% (95% CI: 61-77) and 36% (95% CI: 17-51) for those with onset 14-59 days, 60-119 days and 120-179 days after booster vaccination, respectively.ConclusionsOur results suggest that, during the Omicron period, observed VE against SARI hospitalisation improved with first mRNA booster dose, particularly for those having symptom onset < 120 days after first booster dose.